Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3‐year retrospective cohort study

Background In the developed world, kidney transplantation (KT) in patients with human immunodeficiency virus (HIV) infection is well established. Developing countries concentrate 90% of the people living with HIV, but their experience is underreported. Regional differences may affect outcomes. Objec...

Full description

Saved in:
Bibliographic Details
Published inTransplant infectious disease Vol. 19; no. 4
Main Authors Cristelli, Marina P., Cofán, Federico, Tedesco‐Silva, Helio, Trullàs, Joan Carles, Santos, Daniel Wagner C. L., Manzardo, Christian, Agüero, Fernando, Moreno, Asunción, Oppenheimer, Federico, Diekmann, Fritz, Medina‐Pestana, Jose O., Miro, Jose Maria, Alcaraz, A., Ambrosioni, J., Bodro, M., Blanco, J.L., Brunet, M., Garcia, F., Paredes, D., Esforzado, N., Marcos, M.A., Mallolas, J., Martinez, E., Mosquera, M.D., Musquera, M., Peri, L., Revuelta, I., Ricart, M.J., Soy, D., Torregrosa, J.V., Tuset, M.
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.08.2017
Subjects
Online AccessGet full text
ISSN1398-2273
1399-3062
1399-3062
DOI10.1111/tid.12724

Cover

More Information
Summary:Background In the developed world, kidney transplantation (KT) in patients with human immunodeficiency virus (HIV) infection is well established. Developing countries concentrate 90% of the people living with HIV, but their experience is underreported. Regional differences may affect outcomes. Objectives We compared the 3‐year outcomes of patients with HIV infection receiving a KT in two different countries, in terms of incomes and development. Methods This was an observational, retrospective, double‐center study, including all HIV‐infected patients >18 years old undergoing KT. Results Between 2005 and 2015, 54 KTs were performed (39 in a Brazilian center, and 15 in a Spanish center). Brazilians had less hepatitis C virus co‐infection (5% vs 27%, P=.024). Median cold ischemia time was higher in Brazil (25 vs 18 hours, P=.001). Biopsy‐proven acute rejection (AR) was higher in Brazil (33% vs 13%, P=.187), as were the number of AR episodes (22 vs 4, P=.063). Patient survival at 3 years was 91.3% in Brazil and 100% in Spain; P=.663. All three cases of death in Brazil were a result of bacterial infections within the first year post transplant. At 3 years, survival free from immunosuppressive changes was lower in Brazil (56% vs 90.9%, P=.036). Raltegravir‐based treatment to avoid interaction with calcineurin inhibitor was more prevalent in Spain (80% vs 3%; P<.001). HIV infection remained under control in all patients, with undetectable viral load and no opportunistic infections. Conclusion Important regional differences exist in the demographics and management of immunosuppression and antiretroviral therapy. These details may influence AR and infectious complications. Non‐AIDS infections leading to early mortality in Brazil deserve special attention.
Bibliography:Funding information
The study was partially funded by the Spanish Foundation for AIDS Research and Prevention (FIPSE), Madrid (Spain) grant #24‐0858‐09 and by the RETIC, Red de Sida RD12/0017/0001, FEDER, Instituto de Salud Carlos III, Madrid, Spain. J.M.M. received a personal intensification research grant #INT15/00168 during 2016 from the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid (Spain), and a personal 80:20 research grant from the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain during 2017‐19. C.M. received a personal post‐doctoral research grant (Pla Estratègic de Recerca i Innovació en Salut ‐PERIS‐ 2016/2020) from the ‘Departament de Salut de la Generalitat de Catalunya’, Barcelona, Catalonia, Spain during 2017‐2020.
1
See Appendix
.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:1398-2273
1399-3062
1399-3062
DOI:10.1111/tid.12724